<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01137851</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-256</org_study_id>
    <nct_id>NCT01137851</nct_id>
  </id_info>
  <brief_title>Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients</brief_title>
  <official_title>Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients Treated With Biologic Disease Modifying Antirheumatic Drug (DMARD) Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the impact of patient cost sharing on treatment
      discontinuation of biologic agents in patients with Rheumatoid Arthritis (RA)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of patient cost share on discontinuation</measure>
    <time_frame>Assessed from first prescription date and followed for 1-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>RA-related healthcare utilization and costs</measure>
    <time_frame>Pre-index: 6-month period prior to the index drug date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause healthcare utilization and costs</measure>
    <time_frame>Pre-index: 6-month period prior to the index drug date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA-related healthcare utilization and costs</measure>
    <time_frame>Post-period: Index date+365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause healthcare utilization and costs</measure>
    <time_frame>Post-period: Index date+365 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3940</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>New to bDMARD</arm_group_label>
    <description>New to bDMARD RA patients with high and low cost share who continue or discontinue treatment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Commercial health plan members
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients diagnosed with Rheumatoid Arthritis (RA) who newly initiated a biologic DMARD
        (bDMARD) during a study timeframe of 1/01/06 to 3/31/09.

        Inclusion Criteria:

          -  18 to 64 years of age at index date

          -  Diagnosis of RA during the study period (ICD-9CM 714.xx)

          -  Evidence of at least one biologic DMARD of interest during the study timeframe

          -  Continuous enrollment during the study timeframe

          -  Both medical and pharmacy benefits

          -  No evidence of a claim for a bDMARD in the 6-month pre-period

        Exclusion Criteria:

          -  Patients are excluded if they have a diagnosis of psoriasis, psoriatic arthritis,
             ankylosing spondylitis, Crohn's disease, or ulcerative colitis at any time during the
             study timeframe; have a claim for Rituxan, IV etanercept, or IV adalimumab; or have
             Medicare or Medicaid during the study timeframe
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/home.aspx</url>
    <description>BMS Clinical Trials Disclosure</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2010</study_first_submitted>
  <study_first_submitted_qc>June 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2010</study_first_posted>
  <last_update_submitted>September 30, 2010</last_update_submitted>
  <last_update_submitted_qc>September 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

